Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
AssigneeCelator Pharmaceuticals, Inc.
InventorsDaryl C. Drummond, Bolin Geng, Dmitri B. Kirpotin, Suresh K. Tipparaju, Alexander Koshkaryev, Ozan Alkan
Life of this patent
Estimating the term…
Abstract
Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.
Claims20
A liposome composition comprising an ATR protein kinase inhibitor, or a pharmaceutically acceptable salt thereof, encapsulated in a liposome and having a plasma half-life of at least about 5 hours in mice, wherein the ATR protein kinase inhibitor is a compound of formula (I):
- wherein R is a moiety comprising an amine with a pKa of greater than 7.0;
- and the liposome comprises cholesterol.
An ataxia-telangiectasia and Rad3-related (ATR) protein kinase inhibitor of formula (Ia), or a pharmaceutically acceptable salt thereof:
- wherein R′ is NRaRb, wherein Ra and Rb are each independently C1-C4alkyl.
Dependencies are inferred from the claim text.